CRSP Earnings Date: Nov 9, 2026 (Estimated) — CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology
Updated
When is CRSP's next earnings date?
CRISPR Therapeutics AG (CRSP) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 9:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.04 on revenue of $14.8M.
How did CRSP do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), CRISPR Therapeutics AG posted EPS of -$0.94 versus the -$1.18 estimate, a beat of 20.3%. Revenue was $10.2M against a $7.1M estimate. The stock's 1-day post-earnings move was +7.1%.
How much does CRSP stock move after earnings?
CRSP beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.8% (up or down) in the day after earnings.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -1.18 | -0.94 | +20.34% | $10.2M | ✅ Beat | +7.06% | +7.95% | +14.63% |
| 2026-05-04 | Q1 2026 | -1.22 | -1.28 | -4.92% | $1.5M | ❌ Miss | -2.24% | +0.80% | -2.80% |
| 2026-02-12 | Q4 2025 | -1.20 | -1.37 | -14.17% | $864,000 | ❌ Miss | +8.46% | +9.26% | -1.04% |
| 2025-11-10 | Q3 2025 | -1.30 | -1.17 | +10.00% | $889,000 | ✅ Beat | -0.98% | -4.70% | +3.48% |
| 2025-08-04 | Q2 2025 | -1.43 | -1.29 | +9.79% | $892,000 | ✅ Beat | -6.71% | -7.01% | -11.09% |
| 2025-05-06 | Q1 2025 | -1.25 | -1.58 | -26.40% | $865,000 | ❌ Miss | +3.29% | +12.24% | +16.31% |
| 2025-02-11 | Q4 2024 | -1.21 | -0.44 | +63.64% | $35.7M | ✅ Beat | +9.29% | +33.82% | +5.98% |
| 2024-11-05 | Q3 2024 | -1.42 | -1.01 | +28.87% | $602,000 | ✅ Beat | -0.45% | +8.44% | +1.09% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $10.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue | 98.2% | $10.0M | — | — | — | — | — |
| Grant | 1.8% | $181K | -79.7% | $691K | $865K | $892K | $889K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.